Role of Monocyte Chemoattractant Protein-1 in Cardiovascular Remodeling Induced by Chronic Blockade of Nitric Oxide Synthesis

<jats:p> <jats:italic>Background</jats:italic> —Chronic inhibition of endothelial nitric oxide (NO) synthesis by the administration of <jats:italic>N</jats:italic> <jats:sup>ω</jats:sup> -nitro- <jats:sc>l</jats:sc> -arginine methyl ester (L-NAME) to rats induces early vascular inflammatory changes (monocyte infiltration into coronary vessels and monocyte chemoattractant protein-1 [MCP-1] expression) as well as subsequent arteriosclerosis (medial thickening and perivascular fibrosis) and cardiac fibrosis. However, the role of MCP-1 in this process is not known. </jats:p> <jats:p> <jats:italic>Methods and Results</jats:italic> —We investigated the effect of a specific monoclonal anti–MCP-1 neutralizing antibody in rats treated with L-NAME to determine the role of monocytes in the regulation of cardiovascular remodeling. We found increased expression of MCP-1 mRNA in vascular endothelial cells and monocytes in inflammatory lesions. Cotreatment with an anti–MCP-1 antibody, but not with control IgG, prevented the L-NAME–induced early inflammation and reduced late coronary vascular medial thickening. In contrast, the anti–MCP-1 antibody did not decrease the development of perivascular fibrosis, the expression of transforming growth factor (TGF)-β <jats:sub>1</jats:sub> mRNA, or systolic pressure overload induced by L-NAME administration. </jats:p> <jats:p> <jats:italic>Conclusions</jats:italic> —These results suggest that MCP-1 is necessary for the development of medial thickening as well as monocyte recruitment. In contrast, the pathogenesis of fibrosis may involve other factors, such as TGF-β <jats:sub>1</jats:sub> . </jats:p>